{"id":1961,"date":"2017-03-09T12:29:30","date_gmt":"2017-03-09T12:29:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1961"},"modified":"2021-07-24T12:56:41","modified_gmt":"2021-07-24T07:26:41","slug":"business-cocktail-10","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10","title":{"rendered":"Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69ef3bfeabbb3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69ef3bfeabbb3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10\/#Sanofi_pays_E120M_to_buy_into_AstraZeneca_RSV_program\" >Sanofi pays \u20ac120M to buy into AstraZeneca RSV program<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10\/#Celgene_BMS_Novartis_expected_to_top_2022_orphan_drug_market_worth_209B\" >Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10\/#Thwarted_buyer_Sanofi_tries_its_hand_at_a_21B_European_generics_sale\" >Thwarted buyer Sanofi tries its hand at a $2.1B European generics sale<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10\/#BeiGene_embarks_on_330M_biologics_plant_project_in_China\" >BeiGene embarks on $330M biologics plant project in China<\/a><\/li><\/ul><\/nav><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Sanofi_pays_E120M_to_buy_into_AstraZeneca_RSV_program\"><\/span>Sanofi pays \u20ac120M to buy into AstraZeneca RSV program<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sanofi has paid \u20ac120 million ($126 million) upfront and committed to up to \u20ac495 million more for a stake in AstraZeneca\u2019s experimental monoclonal antibody against respiratory syncytial virus (RSV). The agreement will see Sanofi and AstraZeneca equally share costs and profits for a phase 2b asset with the potential to immunize infants against a virus that kills 160,000 children a year. AstraZeneca\u2019s MedImmune picked up the rights to AIMM Therapeutics\u2019 anti-RSV mAb D25 in 2009, and went on to initiate a phase 2b study in preterm infants in the back half of last year. Now, with the start of a phase 3 study in healthy full-term infants on the horizon, AstraZeneca has brought on board a partner with deep experience of commercializing vaccines and the financial clout to share the burden of pushing MEDI8897 toward approval.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Celgene_BMS_Novartis_expected_to_top_2022_orphan_drug_market_worth_209B\"><\/span>Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Orphan drug growth is set to far outpace the larger pharma industry through 2022. Between 2017 and 2022, orphan drug sales are forecast to balloon 11% annually to $209 billion. That\u2019s about double the growth expected from the overall prescription drug market, and it will be some of the largest drug companies, like Novartis, Roche and Johnson &amp; Johnson, that will be selling them. At the end of the period, Celgene is set to top all competitors in orphan drug sales as blood cancer drug Revlimid makes its climb from nearly $7 billion in 2016 sales to more than $13.5 billion by 2022. Bristol-Myers Squibb, Novartis, Roche and Johnson &amp; Johnson are expected to trail Celgene in that order at the end of the period. The checkpoint inhibitor drug Opdivo is pegged as Europe\u2019s top orphan drug in 2022.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Thwarted_buyer_Sanofi_tries_its_hand_at_a_21B_European_generics_sale\"><\/span>Thwarted buyer Sanofi tries its hand at a $2.1B European generics sale<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>After losing out on two sizable deals, Sanofi recently said the company wasn\u2019t looking to make any big M&amp;A moves right away. Instead, Sanofi might be looking to slim down by prepping the sale of its European generics unit. The French drugmaker wants to hire advisers by the end of this month and conduct an auction after the summer for a deal estimated to be worth about \u20ac2 billion ($2.1 billion). News of a potential sale comes after Brandicourt last month said his company is \u201cnot in a hurry to do M&amp;A.\u201d That represented a significant change from the company\u2019s actions over the last year. Sanofi made several moves during the frenzied Medivation deal fray, only to be beaten out by Pfizer with its $14 billion offer. Then, Sanofi was reportedly in talks to buy Actelion, but that company ultimately went to Johnson &amp; Johnson for $30 billion.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"BeiGene_embarks_on_330M_biologics_plant_project_in_China\"><\/span>BeiGene embarks on $330M biologics plant project in China<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>China\u2019s BeiGene, which is developing a portfolio of immuno-oncology drugs it expects will challenge those of Western drugmakers, has struck a deal with a Chinese development agency to build a biologics plant to manufacture them. The Hong Kong-based company in moving into a joint venture with the Guangzhou Development District for manufacturing facility in Guangzhou, Guangdong Province, China. The JV will invest a total of RMB2.2 billion ($330 million) in the project. The joint venture, BeiGene Biologics, will be funded with an investment of about $30 million from BeiGene HK and $150 million from the district\u2019s Guangzhou GET Technology Development unit, which will make both a cash equity investment in the JV and a shareholder loan. The joint venture also plans to get a $150 million loan.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi pays \u20ac120M to buy into AstraZeneca RSV program Sanofi has paid \u20ac120 million ($126 million) upfront and committed to up to \u20ac495 million more for a stake in AstraZeneca\u2019s experimental monoclonal antibody against respiratory syncytial virus (RSV). The agreement will see Sanofi and AstraZeneca equally share costs and profits for a phase 2b asset [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1040,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[686,96,17485,155,423,17313,460,533],"industry":[17225],"therapeutic_areas":[17233,17231,17228,17243],"class_list":["post-1961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-actelion","tag-astrazeneca","tag-beigene","tag-celgene","tag-novartis","tag-orphan-drug","tag-pfizer","tag-sanofi","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanofi pays \u20ac120M to buy into AstraZeneca RSV program<\/title>\n<meta name=\"description\" content=\"Sanofi has paid \u20ac120 million ($126 million) upfront and committed to up to \u20ac495 million more for a stake in AstraZeneca\u2019s experimental monoclona\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi pays \u20ac120M to buy into AstraZeneca RSV program\" \/>\n<meta property=\"og:description\" content=\"Sanofi has paid \u20ac120 million ($126 million) upfront and committed to up to \u20ac495 million more for a stake in AstraZeneca\u2019s experimental monoclona\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-09T12:29:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"602\" \/>\n\t<meta property=\"og:image:height\" content=\"339\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi pays \u20ac120M to buy into AstraZeneca RSV program","description":"Sanofi has paid \u20ac120 million ($126 million) upfront and committed to up to \u20ac495 million more for a stake in AstraZeneca\u2019s experimental monoclona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10","og_locale":"en_US","og_type":"article","og_title":"Sanofi pays \u20ac120M to buy into AstraZeneca RSV program","og_description":"Sanofi has paid \u20ac120 million ($126 million) upfront and committed to up to \u20ac495 million more for a stake in AstraZeneca\u2019s experimental monoclona","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-03-09T12:29:30+00:00","article_modified_time":"2021-07-24T07:26:41+00:00","og_image":[{"width":602,"height":339,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10","name":"Sanofi pays \u20ac120M to buy into AstraZeneca RSV program","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","datePublished":"2017-03-09T12:29:30+00:00","dateModified":"2021-07-24T07:26:41+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Sanofi has paid \u20ac120 million ($126 million) upfront and committed to up to \u20ac495 million more for a stake in AstraZeneca\u2019s experimental monoclona","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-10"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-10#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","width":602,"height":339},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Actelion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BeiGene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Orphan Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Actelion<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">BeiGene<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Orphan Drug<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 9, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 9, 2017 12:29 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1961"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1961\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1040"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1961"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1961"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}